Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용수 | - |
dc.date.accessioned | 2016-05-27T08:16:06Z | - |
dc.date.available | 2016-05-27T08:16:06Z | - |
dc.date.issued | 2015-01 | - |
dc.identifier.citation | DIABETES RESEARCH AND CLINICAL PRACTICE, v. 107, NO 1, Page. 139-147 | en_US |
dc.identifier.issn | 0168-8227 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/21419 | - |
dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S0168822714004264 | - |
dc.description.abstract | Aims: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of IDeg and IAsp. This pan-Asian, 26-week trial investigated efficacy and safety of IDegAsp vs biphasic insulin aspart 30 (BIAsp 30) in Asian adults with type 2 diabetes (T2DM), inadequately controlled on once-or twice-daily (BID) basal, premixed or self-mixed insulin. Methods: Participants (mean age 59.8 years, HbA1c 8.4%, FPG 7.9 mmol/L, BMI 25.4 kg/m2) were randomised 2: 1 to BID IDegAsp (n = 282) or BIAsp 30 (n = 142) and continued existing metformin treatment. Insulins were administered with breakfast and main evening meal, titrated to a pre-breakfast and pre-main evening meal self-measured plasma glucose target of 4-5 mmol/L. Results: IDegAsp achieved the primary endpoint of non-inferiority to BIAsp 30 for mean change in HbA1c (estimated treatment difference [ETD] IDegAsp-BIAsp 30: 0.05% points [95% CI +/- 0.10 | en_US |
dc.description.sponsorship | The authors would like to acknowledge the investigators of the BOOST Intensify All Trial (see Supplementary appendix). Medical writing support was provided by apothecom scopemedical ltd and funded by Novo Nordisk A/S. The study was funded by Novo Nordisk A/S (ClinicalTrials.gov identifier: NCT01059812). | - |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER IRELAND LTD | en_US |
dc.subject | Insulin degludec | en_US |
dc.subject | Insulin aspart | en_US |
dc.subject | Type 2 diabetes | en_US |
dc.subject | HbA1c | en_US |
dc.title | Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 107 | - |
dc.identifier.doi | 10.1016/j.diabres.2014.09.026 | - |
dc.relation.page | 139-147 | - |
dc.relation.journal | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.contributor.googleauthor | Kaneko, Shizuka | - |
dc.contributor.googleauthor | Chow, Francis | - |
dc.contributor.googleauthor | Choi, Dong Seop | - |
dc.contributor.googleauthor | Taneda, Shinji | - |
dc.contributor.googleauthor | Hirao, Koichi | - |
dc.contributor.googleauthor | Park, Yongsoo | - |
dc.contributor.googleauthor | Andersen, Thomas Hasseriis | - |
dc.contributor.googleauthor | Gall, Mari-Anne | - |
dc.contributor.googleauthor | Christiansen, Jens Sandahl | - |
dc.relation.code | 2015002769 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | parkys | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.